These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Substrate and inhibitor selectivity of human heart monoamine oxidase. Parkinson D; Callingham BA Biochem Pharmacol; 1979 May; 28(10):1639-43. PubMed ID: 38793 [No Abstract] [Full Text] [Related]
4. Monoamine oxidase-III. Further studies of inhibition by propargylamines. Williams CH; Lawson J Biochem Pharmacol; 1975 Oct; 24(20):1889-91. PubMed ID: 1191339 [No Abstract] [Full Text] [Related]
5. Inhibition by clorgyline and deprenyl of the different forms of monoamine oxidase in rat liver mitochondria. Egashira T; Ekstedt B; Oreland L Biochem Pharmacol; 1976 Dec; 25(23):2583-6. PubMed ID: 985579 [No Abstract] [Full Text] [Related]
6. Enhancement of rat brain cytosolic monoamine oxidase activity by clorgyline. Comparison with (-)-deprenyl and MDL 72145. Azam M; Jain S; Baquer NZ Biochem Pharmacol; 1990 Nov; 40(10):2215-8. PubMed ID: 2123104 [TBL] [Abstract][Full Text] [Related]
7. Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat. Benedetti MS; Boucher T; Carlsson A; Fowler CJ Biochem Pharmacol; 1983 Jan; 32(1):47-52. PubMed ID: 6830619 [TBL] [Abstract][Full Text] [Related]
8. Substrate specificity and inhibitor sensitivity of monoamine oxidase in rat kidney mitochondria. Lyles GA; Shaffer CJ Biochem Pharmacol; 1979 Apr; 28(7):1099-106. PubMed ID: 444267 [No Abstract] [Full Text] [Related]
9. Substrate specificity of the different forms of monoamine oxidase in rat liver mitochondria. Ekstedt B Biochem Pharmacol; 1976 May; 25(10):1133-8. PubMed ID: 938537 [No Abstract] [Full Text] [Related]
10. Potentiation of the inhibition of rat liver monoamine oxidase-a by clorgyline after pretreatment with SKF 525A. Fowler CJ Med Biol; 1980 Oct; 58(5):285-7. PubMed ID: 7206835 [TBL] [Abstract][Full Text] [Related]
11. A method for the determination of platelet and plasma monoamine oxidase in whole blood. Marshall EF; Campbell IC Biochem Pharmacol; 1977 Feb; 26(4):353-4. PubMed ID: 849328 [No Abstract] [Full Text] [Related]
12. Monoamine oxidase in human platelets. Kinetics and methodological aspects. Koide Y; Koide N; Ross S; Sääf J; Wetterberg L Biochem Pharmacol; 1981 Nov; 30(21):2893-900. PubMed ID: 7317084 [No Abstract] [Full Text] [Related]
13. A comparison of cardiac and vascular clorgyline-resistant amine oxidase and monoamine oxidase. Inhibition by amphetamine, mexiletine and other drugs. Clarke DE; Lyles GA; Callingham BA Biochem Pharmacol; 1982 Jan; 31(1):27-35. PubMed ID: 7059347 [No Abstract] [Full Text] [Related]
14. Distribution and inhibition characteristics of human brain monoamine oxidase. Owen F; Cross AJ; Lofthouse R; Glover V Biochem Pharmacol; 1979 Apr; 28(7):1077-80. PubMed ID: 444264 [No Abstract] [Full Text] [Related]
15. Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase. Donnelly CH; Murphy DL Biochem Pharmacol; 1977 May; 26(9):853-8. PubMed ID: 861051 [No Abstract] [Full Text] [Related]
17. Metabolism of octopamine in vitro by monoamine oxidase in some rat tissues. Lyles GA Life Sci; 1978 Jul; 23(3):223-30. PubMed ID: 357872 [No Abstract] [Full Text] [Related]
18. The heterogeneity of monoamine oxidase in distinct populations of rat brain mitochondria. Owen F; Bourne R Biochem Pharmacol; 1977 Feb; 26(4):289-92. PubMed ID: 849318 [No Abstract] [Full Text] [Related]
19. Modification of brain mitochondrial monoamine oxidase activities by hydroxyethylhydrazide of cyanoacetic acid and some other monoamine oxidase inhibitors. Baumanis EA; Kalnina IE; Moskvitina TA; Gorkin VZ Biochem Pharmacol; 1977 Jun; 26(11):1059-63. PubMed ID: 18152 [No Abstract] [Full Text] [Related]